Development, calibration, and validation of a U.S. white male population-based simulation model of esophageal adenocarcinoma

PLoS ONE

Volumn 5, Issue 3, 2010, Pages

  Hur, Chin ^a,b   Hayeck, Tristan J ^a   Yeh, Jennifer M ^c   Richards, Ethan B ^a   Spechler, Stuart J ^d   Gazelle, G Scott ^a,b,c   Kong, Chung Yin ^a,b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^d UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTINEOPLASTIC AGENT;

ADULT; AGED; ANALYSIS; ARTICLE; CALIBRATION; CANCER DIAGNOSIS; CANCER GROWTH; CANCER INCIDENCE; CANCER MORTALITY; CANCER SCREENING; CAUCASIAN; CHEMOPROPHYLAXIS; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGUS MUCOSA; HEALTH STATUS; HISTORY; HUMAN; MAJOR CLINICAL STUDY; MALE; MATHEMATICAL MODEL; MEDICAL LITERATURE; MORBIDITY; OUTCOME ASSESSMENT; POLICY; POPULATION; PRECANCER; PREVALENCE; RETROSPECTIVE STUDY; SIMULATION; UNITED STATES; VALIDATION STUDY; ADENOCARCINOMA; ALGORITHM; COST BENEFIT ANALYSIS; DISEASE COURSE; ESOPHAGUS TUMOR; ETHNOLOGY; PROBABILITY; THEORETICAL MODEL;

ADENOCARCINOMA; ADULT; ALGORITHMS; ANTICARCINOGENIC AGENTS; ASPIRIN; CALIBRATION; COST-BENEFIT ANALYSIS; DISEASE PROGRESSION; ESOPHAGEAL NEOPLASMS; EUROPEAN CONTINENTAL ANCESTRY GROUP; HUMANS; MALE; MARKOV CHAINS; MODELS, THEORETICAL; UNITED STATES;

EID: 77949766852     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0009483     Document Type: Article

References (43)

1. Brown LM, Devesa SS, Chow WH (2008) Incidence of Adenocarcinoma of the Esophagus Among White Americans by Sex, Stage, and Age. J Natl Cancer Inst.
2. Ries LAG, Melbert D, Krapcho M, Stinchcomb DG, et al. SEER(1975-2005),SEER Cancer Statistics Review, 1975-2005. National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975-2005/based on November 2007 SEER data submission, posted to the SEER web site, 2008.
3. Locke GR, 3rd, Talley NJ, Fett SL, Zinsmeister AR, Melton LJ, 3rd (1997) Prevalence and clinical spectrum of gastroesophageal reflux: a population-based study in Olmsted County, Minnesota. Gastroenterology 112: 1448-1456.
4. Williamson WA, Ellis FH, Jr., Gibb SP, Shahian DM, Aretz HT, et al. (1991) Barrett's esophagus. Prevalence and incidence of adenocarcinoma. Arch Intern Med 151: 2212-2216.
5. Shaheen NJ, Crosby MA, Bozymski EM, Sandler RS (2000) Is there publication bias in the reporting of cancer risk in Barrett's esophagus? Gastroenterology 119: 333-338.
6. Goldie SJ, Goldhaber-Fiebert JD, Garnett GP (2006) Chapter 18: Public health policy for cervical cancer prevention: the role of decision science, economic evaluation, and mathematical modeling. Vaccine 24 Suppl 3: S3/155-163.
7. Hur C, Nishioka NS, Gazelle GS (2004) Cost-effectiveness of aspirin chemoprevention for Barrett's esophagus. J Natl Cancer Inst 96: 316-325.
8. Chak A, Faulx A, Eng C, Grady W, Kinnard M, et al. (2006) Gastroesophageal reflux symptoms in patients with adenocarcinoma of the esophagus or cardia. Cancer 107: 2160-2166.
9. Hur C. Advancing an evidence-based approach to Barrett's esophagus: A health outcomes research workshop; 2007; Boston, MA.
10. Gerson LB, Shetler K, Triadafilopoulos G (2002) Prevalence of Barrett's esophagus in asymptomatic individuals. Gastroenterology 123: 461-467.
11. Rex DK, Cummings OW, Shaw M, Cumings MD, Wong RK, et al. (2003) Screening for Barrett's esophagus in colonoscopy patients with and without heartburn. Gastroenterology 125: 1670-1677.
12. Ronkainen J, Pertti A, Storskrubb T, Johansson S-E, Linde T, et al. (2005) Prevalence of Barrett's esophagus in the general population: an endoscopic study. Gastroenterology 129: 1825-1831.
13. Menke-Pluymers MB, Hop WC, Dees J, van Blankenstein M, Tilanus HW (1993) Risk factors for the development of an adenocarcinoma in columnar-lined (Barrett) esophagus. The Rotterdam Esophageal Tumor Study Group. Cancer 72: 1155-1158.
14. Locke 3rd GR, Talley NJ, Fett SL, Zinsmeister AR, Melton3rd LJM (1997) Prevalence and clinical spectrum of gastroesophageal reflux: a population-based study in Olmsted County, Minnesota. Gastroenterology 112: 1148-1156.
15. El-Serag HB (2007) Time Trends of Gastroesophageal Reflux Disease: A Systematic Review. Clinical Gastroenterology and Hepatology 5: 17-26.
16. Valle C, Broglia F, Pistorio A (1999) Prevalence and impact of symptoms suggestive of gastroesophageal reflux disease. Digestive Diseases and Sciences 44: 1848-1852.
17. Chiocca JC, Olmos JA, Salis GB, Soifer LO, Higa R, et al. (2005) Prevalence, clinical spectrum and atypical symptoms of gastro-oesophageal reflux in Argentina: a nationwide population-based study. Alimentary Pharmacology and Therapeutics 22: 331-342.
18. El-Serag HB, Petersen NJ, Carter J, Graham DY, Richardson P, et al. (2004) Gastroesophageal Reflux Among Different Racial Groups in the United States. Gastroenterology 126: 1692-1699.
19. Isolauri J, Laippala P (1995) Prevalence of Symptoms Suggestive of Gastroesophageal Reflux Disease in an Adult Population. Annals of Internal Medicine 27: 67-70.
20. Mohammed I, Cherkas LF, Riley SA, Spector TD, Trudgill NJ (2003) Genetic influences in gastro-oesophageal reflux disease: a twin study. Gut 52: 1085-1089.
21. Terry P, Lagergren J, Wolk A, Nyren O (2000) Reflux-Inducing Dietary Factors and Risk of Adenocarcinoma of the Esophagus and Gastric Cardia. Nutrition and Cancer 38: 186-191.
22. Collen MJ, Abdulian JD, Chen YK (1995) Gastroesophageal Reflux Disease in the Elderly: More Severe Disease That Requires Aggressive Therapy. American Journal of Gastroenterology 90: 1053-1057.
23. Talley NJ, Zinsmeister AR, Schleck CD, Melton 3rd LJ (1992) Dyspepsia and Dyspepsia Subgroups: A Population-Based Study. Gastroenterology 102: 1259-1268.
24. Diaz-Rubio M, Moreno-Elola-Olaso C, Rey E, Locke 3rd GR, Rodriguez-Artalejo F (2004) Symptoms of gastro-oesophageal reflux: prevalence, severity, duration and associated factors in a Spanish population. Alimentary Pharmacology and Therapeutics 19: 95-105.
25. Cameron AJ, Lomboy CT (1992) Barrett's esophagus: age, prevalence, and extent of columnar epithelium. Gastroenterology 103: 1241-1245.
26. Clark GWB, Ireland AP, Peters JH, Chandrasoma P, DeMeester TR, et al. (1997) Short-segment Barrett's esophagus: A prevalent complication of gastroesophageal reflux disease with malignant potential. Journal of Gastrointestinal Surgery 1: 113-122.
27. O'Connor JB, Falk GW, Richter JE (1999) The incidence of adenocarcinoma and dysplasia in Barrett's esophagus: report on the Cleveland Clinic Barrett's Esophagus Registry. Am J Gastroenterol 94: 2037-2042.
28. Corley DA, Levin TR, Habel LA, Weiss NS, Buffler PA (2002) Surveillance and survival in Barrett's adenocarcinomas: a population-based study. Gastroenterology 122: 633-640.
29. Corey KE, Schmitz SM, Shaheen NJ (2003) Does a surgical antireflux procedure decrease the incidence of esophageal adenocarcinoma in Barrett's esophagus? A meta-analysis. Am J Gastroenterol 98: 2390-2394.
30. Westhoff B, Brotze S, Weston A, McElhinney C, Cherian R, et al. (2005) The frequency of Barrett's esophagus in high-risk patients with chronic GERD. Gastrointest Endosc 61: 226-231.
31. Pera M (2003) Trends in incidence and prevalence of specialized intestinal metaplasia, barrett's esophagus, and adenocarcinoma of the gastroesophageal junction. World Journal of Surgery 27: 999-1008.
32. Guanrei Y, Songliang Q, He H, Guizen F (1988) Natural history of early esophageal squamous carcinoma and early adenocarcinoma of the gastric cardia in the People's Republic of China. Endoscopy 20: 95-98.
33. Kirkpatrick S, Gelatt CD, Jr., Vecchi MP (1983) Optimization by Simulated Annealing. Science 220: 671-680.
34. Jeon J, Luebeck EG, Moolgavkar SH (2006) Age effects and temporal trends in adenocarcinoma of the esophagus and gastric cardia (United States). Cancer Causes Control 17: 971-981.
35. Zheng T, Holford TR, Boyle P, Chen Y, Ward BA, et al. (1994) Time trend and the age-period-cohort effect on the incidence of histologic types of lung cancer in Connecticut, 1960-1989. Cancer 74: 1556-1567.
36. Corley DA, Kerlikowske K, Verma R, Buffler P (2003) Protective association of aspirin/NSAIDs and esophageal cancer: a systematic review and meta-analysis. Gastroenterology 124: 47-56.
37. Stout NK, Knudsen AB, Kong CY, McMahon PM, Gazelle GS (2009) Calibration methods used in cancer simulation models and suggested reporting guidelines. Pharmacoeconomics 27: 533-545.
38. Provenzale D, Kemp JA, Arora S, Wong JB (1994) A guide for surveillance of patients with Barrett's esophagus. Am J Gastroenterol 89: 670-680.
39. Provenzale D, Schmitt C, Wong JB (1999) Barrett's esophagus: a new look at surveillance based on emerging estimates of cancer risk. Am J Gastroenterol 94: 2043-2053.
40. Inadomi JM, Sampliner R, Lagergren J, Lieberman D, Fendrick AM, et al. (2003) Screening and surveillance for Barrett esophagus in high-risk groups: a cost-utility analysis. Ann Intern Med 138: 176-186.
41. Gerson LB, Groeneveld PW, Triadafilopoulos G (2004) Cost-effectiveness model of endoscopic screening and surveillance in patients with gastroesophageal reflux disease. Clin Gastroenterol Hepatol 2: 868-879.
42. Jankowski J, Moayyedi P (2004) Re: Cost-effectiveness of aspirin chemoprevention for Barrett's esophagus. J Natl Cancer Inst 96: 885-887; author reply.
43. Westhoff B, Brotze S, Weston A, McElhinney C, Cherian R, et al. (2005) The frequency of Barrett's esophagus in high-risk patients with chronic GERD. Gastrointestinal Endoscopy 61: 226-231.